GLP-1 Agonist Phase III

Cagrilintide

Also known as: NN9838, AM833, CagriSema (combination)

A long-acting amylin analog that amplifies weight loss when paired with semaglutide — the amylin component of CagriSema's ~25% body weight reduction.

Popularity B+
Class Long-Acting Amylin Analog
Half-Life ~7 days (160-170 hours)
Form Pre-filled pen (clinical), Lyophilized powder (research)
View Vendors → Jump to Dosing ↓
Cagrilintide C190H299N51O63
Research-Backed User Reports Sourced Updated Mar 2026
// Overview

What is Cagrilintide?

Cagrilintide is a long-acting analog of amylin, a hormone co-secreted with insulin from pancreatic beta cells after meals. Amylin naturally contributes to satiety signaling, gastric emptying regulation, and glucagon suppression — but native amylin has a half-life of only minutes, making it impractical as a therapeutic.

Novo Nordisk developed cagrilintide with acylation technology (similar to semaglutide) to extend its half-life to approximately one week, enabling once-weekly subcutaneous injection. The compound is being developed both as a standalone therapy and as the amylin component of CagriSema — a fixed-dose combination of cagrilintide and semaglutide 2.4mg.

CagriSema represents a next-generation approach to obesity, combining two distinct satiety pathways (GLP-1 and amylin) for additive weight loss effects. Phase 3 trials showed CagriSema producing approximately 22-25% body weight loss, matching or exceeding tirzepatide’s efficacy.

Looking for the best vendor deals?

Compare prices across 10+ peptide and anabolic vendors. Find the best quality at the lowest price.

Compare Vendors
// How It Works

How Cagrilintide Works

Cagrilintide mimics the satiety effects of native amylin through distinct pathways from GLP-1:

  1. Amylin receptor activation — Binds to amylin receptors (calcitonin receptor + RAMP complexes) in the area postrema and hypothalamus, producing feelings of fullness and satiety.
  2. Gastric emptying delay — Slows gastric emptying through vagal pathways, prolonging the feeling of fullness after meals.
  3. Glucagon suppression — Inhibits post-prandial glucagon secretion, reducing hepatic glucose output and improving glycemic control.
  4. Complementary to GLP-1 — The amylin pathway is neuroanatomically distinct from GLP-1 signaling. Combining both (CagriSema) produces additive appetite suppression through parallel satiety circuits.
  5. Acylation for half-life extension — A fatty acid sidechain binds to albumin, extending the half-life from minutes to ~7 days for weekly dosing.
// Dosage Protocols

Dosage Information (User-Reported)

Disclaimer: Dosage information is compiled from user reports and published research. This is not medical advice. Consult a healthcare professional before use.
Level Dose Frequency Duration
Monotherapy 2.4 mg Once weekly Ongoing
CagriSema (with sema) 2.4 mg cagri + 2.4 mg sema Once weekly (combined pen) Ongoing
Titration Start low, increase every 4 weeks Weekly Until therapeutic dose

What to Expect

Week 1-4

Appetite reduction begins. Nausea possible during titration (amylin and GLP-1 both affect GI). Satiety between meals increases.

Week 5-12

Strong appetite suppression. Weight loss trajectory 1-2 lbs/week. Nausea typically improving.

Month 3-6

Substantial weight loss (15-20% range with CagriSema). Body composition improving significantly.

Month 6-12

Approaching peak weight loss. CagriSema users report 20-25% total body weight reduction. Metabolic panels showing comprehensive improvement.

Common Stacks

Semaglutide

CagriSema Protocol

The designed combination — amylin + GLP-1 produces additive weight loss through parallel satiety pathways

BPC-157

GI Comfort

Manages the amplified GI effects of dual-pathway appetite suppression

Creatine Monohydrate

Lean Mass Support

Preserves muscle during the substantial weight loss CagriSema produces

// Preparation

Reconstitution & Storage

Research-grade: Reconstitute with bacteriostatic water per standard protocol. Clinical CagriSema pens are pre-filled.

Storage: Refrigerate 2-8°C. Protect from light. Do not freeze.

Ready to source Cagrilintide?

Compare prices across verified vendors. Find the best purity at the lowest price.

Compare Vendors →
// Safety Profile

Side Effects & Safety

Potential Side Effects

  • ! Nausea (most common, dose-dependent)
  • ! Vomiting
  • ! Diarrhea
  • ! Constipation
  • ! Injection site reactions
  • ! Decreased appetite
  • ! Abdominal pain
  • ! Similar GI profile to other incretins, may be amplified in CagriSema combination

Contraindications

  • ⚠ Personal or family history of medullary thyroid carcinoma (caution, class-related)
  • ⚠ Pregnancy or breastfeeding
  • ⚠ History of pancreatitis
  • ⚠ Severe gastrointestinal disease
  • ⚠ Gastroparesis

Legal & Regulatory Status

Investigational — not yet FDA-approved. Phase 3 trials ongoing. CagriSema expected to be submitted for FDA approval. Research-grade available from select peptide vendors.

// Research

Published Research

// Where to Buy

Top Vendors for Cagrilintide

Ranked by our review scores. All vendors are independently tested.

B+
Read Review Visit Vendor →
B+
Read Review Visit Vendor →
B+
Read Review Visit Vendor →
// Related Compounds

Other GLP-1 Agonist Guides

BPC-157 Arginate (Oral)

The oral form of BPC-157 — gastric-acid stable and designed for direct GI tract healing. No injections needed…

Read Guide →

TB-500 Fragment

A concentrated fragment of Thymosin Beta-4 focused on the core actin-binding domain — smaller molecule, targeted tissue repair.

Read Guide →

5-Amino-1MQ

An NNMT inhibitor that restores NAD+ in fat cells, shifting adipose tissue from storage mode back to metabolically…

Read Guide →

Stay informed on Cagrilintide.

New research, dosage updates, and vendor deals. Straight to your inbox.

Free forever. No spam. Unsubscribe anytime.

This content is for informational and educational purposes only. Cagrilintide is sold for research purposes. Never Natty does not condone or encourage the use of any substance in violation of any laws. Consult a healthcare professional before using any compound discussed on this site.